Skip to content

Free cash flow at other companies

Pfizer logo
PfizerPFE
$2.18B+23.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$60.24M-107%
Insmed logo
InsmedINSM
-$226.22M+16.9%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
-$34.38M-369%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%

Valuation

See full
Market cap$1.82B-63.1%
Enterprise value$1.56B-67.2%
P/S0.8×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Calculated from Sarepta Therapeutics, Inc.’s reported figures.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s free cash flow?
Sarepta Therapeutics, Inc. (SRPT) reported free cash flow of -$204.76M in Q1 2026.
How has Sarepta Therapeutics, Inc.'s free cash flow changed year-over-year?
Sarepta Therapeutics, Inc.'s free cash flow increased by 67.3% year-over-year, from -$627.09M to -$204.76M.
What is the long-term trend for Sarepta Therapeutics, Inc.'s free cash flow?
Over 2 years (2021 to 2023), Sarepta Therapeutics, Inc.'s free cash flow has grown at a 9.5% compound annual growth rate (CAGR), from -$481.66M to -$577.1M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.